Abstract
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureMohammad Almasri, Maria Elena Carazzolo, Luca Cividini, Valentina Tabanelli, Federica Melle, Elisa Genuardi, Chiara Cosentino, Matteo Bellia, Abdurraouf Mokhtar Mahmoud, Andrea Evangelista, Francesca Maria Quaglia, Stefano Fiori, Riccardo Bomben, Maria Chiara Tisi, Marcello Riva, Anna Merli, Francesco Rotondo, Paolo Corradini, Lucia Farina, Claudia Castellino, Alessia Castellino, Vittorio Ruggero Zilioli, Cristina Muzi, Francesco Piazza, Alessandro Re, Stefan Hohaus, Francesca Gaia Rossi, Gerardo Musuraca, Alice Di Rocco, Benedetta Puccini, Roberta Sciarra, Filippo Ballerini, Federica Cavallo, Riccardo Bruna, Alessia Moioli, Andrea Bernardelli, Caterina Patti, Jacopo Olivieri, Benedetta Bianchi, Michele Spina, Sara Veronica Usai, Piero Maria Stefani, Daniela Drandi, Pierluigi Zinzani, Andres J. M. Ferreri, Monica Balzarotti, Marco Ladetto, Simone Ferrero, Stefano A. Pileri, Carlo Visco
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes
10.1182/blood.2020005289 · 2020
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study
10.3324/haematol.2018.214056 · 2020
The integration of gene mutations and copy number variations refines the prognosis of mantle cell lymphoma: long-term results of the Fondazione Italiana Linfomi MCL0208 clinical trial
10.1038/s41375-025-02795-0 · 2026
Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing
10.1182/blood.2019002385 · 2020
UBR5 HECT domain mutations identified in mantle cell lymphoma control maturation of B cells
10.1182/blood.2019002102 · 2020
Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in mantle cell lymphoma: results from the EU-MCL network trials
10.1038/s41375-024-02375-8 · 2024
Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphoma
10.1038/s41467-025-64666-7 · 2025
MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma
10.3324/haematol.2019.243071 · 2021
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma
10.1182/blood-2015-02-628792 · 2015
Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma
10.1172/jci153283 · 2022
Secondary genetic events and their relationship to TP53 mutation in mantle cell lymphoma: a sub-study from the FIL_MANTLE-FIRST BIO on behalf of Fondazione Italiana Linfomi (FIL)
10.3390/cancers17244027 · 2025
Clinical impact of immunoglobulin heavy chain repertoire in mantle cell lymphoma: a study from the Fondazione Italiana Linfomi (FIL) phase III MCL0208 trial
10.1002/hem3.70285 · 2026
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
10.1016/s0140-6736(24)00184-3 · 2024
Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma
10.1056/nejmoa2201817 · 2022
Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma
10.1200/jco-25-00690 · 2025
Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 study
10.1016/s2352-3026(25)00252-2 · 2025
Integration of [18F]FDG-PET radiomics with liquid biopsy improves outcome prediction in newly diagnosed diffuse large B-cell lymphoma
10.1038/s41375-025-02688-2 · 2025
Molecular clustering on ctDNA improves the prognostic stratification of patients with DLBCL compared with ctDNA levels
10.1182/bloodadvances.2024014136 · 2025
CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing
10.1371/journal.pcbi.1004873 · 2016
Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study
10.1038/s41591-019-0380-z · 2019
Parent-specific copy number in paired tumor-normal studies using circular binary segmentation
10.1093/bioinformatics/btr329 · 2011
A faster circular binary segmentation algorithm for the analysis of array CGH data
10.1093/bioinformatics/btl646 · 2007
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma
10.1073/pnas.0710052104 · 2007
Maftools: efficient and comprehensive analysis of somatic variants in cancer
10.1101/gr.239244.118 · 2018
TP53 gain-of-function and non-gain-of-function mutations are associated with differential prognosis in advanced pancreatic ductal adenocarcinoma
10.1200/po.22.00570 · 2023
TP53 mutation heterogeneity reveals distinct prognoses in mantle cell lymphoma
10.1007/s00277-026-06771-1 · 2026
TP53 mutations in mantle cell lymphoma: from backup to game changer
10.3390/jcm14238480 · 2025
CD36, a signaling receptor and fatty acid transporter that regulates immune cell metabolism and fate
10.1084/jem.20211314 · 2022
CD36: an emerging therapeutic target for cancer and its molecular mechanisms
10.1007/s00432-022-03957-8 · 2022
Deciphering the elevated lipid via CD36 in mantle cell lymphoma with bortezomib resistance using synchrotron-based Fourier transform infrared spectroscopy of single cells
10.3390/cancers11040576 · 2019
CD36 drives metastasis and relapse in acute myeloid leukemia
10.1158/0008-5472.can-22-3682 · 2023
Role of CD36 in cancer progression, stemness, and targeting
10.3389/fcell.2022.1079076 · 2022
STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells
10.18632/oncotarget.25066 · 2018
ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker
10.1038/s41375-025-02615-5 · 2025
Fundamental prognostic difference of ATM gene mutation and deletion in newly diagnosed mantle cell lymphoma
10.1186/s10020-025-01376-2 · 2025
ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks
10.1038/s41467-018-07729-2 · 2019
Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial
10.1016/s0140-6736(25)01432-1 · 2025
Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial
10.1182/blood.2020008727 · 2021
Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation
10.1182/blood.2024025563 · 2025
Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
10.1016/s1470-2045(24)00682-x · 2025
No additional external references are available.